Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160524 · ClinicalTrials.gov registry record · Phase 3
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 596
- Enrollment target
NCT00160524 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 596 participants.
The verdict
NCT00160524, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 596 participants
- Enrollment target
Study Summary
An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\]).
Interventions
- BIOLOGICAL Certolizumab Pegol (CDP870)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2004-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160524
The ClinicalTrials.gov registry entry for NCT00160524 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 596 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol (CDP870) is the first listed.
NCT00160524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00160524 about?
NCT00160524 is a clinical study titled "A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]". An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\]).
What is the current status of trial NCT00160524?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 596 participants. The study started on 2004-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00160524?
The interventions under investigation include: Certolizumab Pegol (CDP870) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00160524?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.